Are Peptides Legal in California? (2026)

By the Peptide Bureau Research Team Regulation Reviewed by the Peptide Bureau Research Team on 28 September 2026

Not legal advice. This page summarises public statutes, board statements and enforcement records for California as of 28 September 2026, for general information. It is not a legal opinion. Laws change; check the linked sources or a licensed California attorney before relying on anything here. Compounds are discussed in a research context only.

Short answer. There is no California statute that bans buying or possessing research peptides as a category. Federal law does the regulating: selling an unapproved peptide for human use is a federal violation by the seller, and human growth hormone has its own federal statute. The Bureau found no peptide that California has scheduled or banned on its own. The California Board of Pharmacy has taken a position on compounded semaglutide or tirzepatide, which matters if you are looking at a clinic or telehealth prescription rather than a research vial. Verified against the sources listed at the bottom on 28 September 2026. Not legal advice.

California at a glance

State controlled-substances law: Cal. Health & Safety Code § 11000 et seq. (California Uniform Controlled Substances Act); Schedule III at § 11056 (leginfo.legislature.ca.gov)
Human growth hormone under state law: Not separately scheduled; the federal statute 21 U.S.C. § 333(e) applies (Health & Safety Code § 11056(f), as amended by AB 1152 (Stats. 2025, ch. 183), effective 1 January 2026) (leginfo.legislature.ca.gov)
Research peptides scheduled by the state: None found
Board of Pharmacy on compounded GLP-1s: The Board of Pharmacy adopted revised compounding regulations on 17 June 2025 (16 CCR §§ 1735.1, 1736.1, 1735.8 and 1736.8), effective 1 October 2025: a compound with the same active ingredient as a commercial product is essentially a copy unless the pharmacist verifies and documents a clinically significant, patient-specific difference, and certificates of analysis must name the actual manufacturer of the active ingredient. The rules are aimed at compounded semaglutide and tirzepatide (2025-10-01) (frierlevitt.com)
Medical board on peptide prescribing: No statement located
GLP-1 by telehealth: Yes. Business and Professions Code § 2242 requires an appropriate prior examination before prescribing, which does not require a synchronous interaction and may be done by telehealth, including a questionnaire, if the standard of care is met. Out-of-state pharmacies shipping compounded products into California need a nonresident pharmacy permit. (leginfo.legislature.ca.gov)
State-level enforcement, 2023 to 2026: 1 action found
Last verified: 28 September 2026, confidence high

The federal rules that apply in California, as everywhere

Federal law is the same in every state, and it is where almost all of the legal weight sits. Under the Federal Food, Drug, and Cosmetic Act a product intended to treat a condition or change how the body works is a drug, and an unapproved new drug cannot be introduced into interstate commerce. That rule binds the seller, not the buyer. The FDA's 2026 warning letters to research-peptide vendors say the same thing eleven times over: a "research use only" label does not help when the website, the bundled bacteriostatic water or a dosing calculator shows the product is meant for human use. The Bureau's enforcement tracker lists every letter, case and lawsuit with its source.

Three federal points matter for a reader in California:

Human growth hormone is the exception. 21 U.S.C. § 333(e) makes it a federal offence to distribute or possess somatropin for any use not approved by the Secretary of HHS. That statute covers HGH itself, not the secretagogues (sermorelin, ipamorelin, CJC-1295) that prompt the body's own release.
Compounding is a separate track. A licensed pharmacy may only compound from bulk substances on the FDA's 503A list. BPC-157, TB-500, MOTS-c, KPV, Semax and Epitalon were moved to Category 2 in September 2023, removed from it in April 2026, and recommended for the list by the FDA's advisory committee on 23 and 24 July 2026. No rule has followed as of September 2026, so they still cannot be legally compounded anywhere, including California. The PCAC vote page has every tally.
GLP-1 compounding is closing, not opening. The FDA has declared the semaglutide and tirzepatide shortages over, proposed in April 2026 to keep both off the 503B bulks list, and sent batches of letters to telehealth sellers in March and June 2026. Vials sold as "GLP-1 S" or "GLP-3 R" for research are unapproved new drugs in the FDA's view wherever the buyer lives.

What California law adds

California's controlled-substances law (Cal. Health & Safety Code § 11000 et seq. (California Uniform Controlled Substances Act); Schedule III at § 11056) decides whether possessing a compound is a state offence. Peptides only become a state-law problem if they appear in those schedules or in a specific state ban. (leginfo.legislature.ca.gov)

The Bureau found no research peptide (BPC-157, TB-500, ipamorelin, sermorelin, semaglutide, tirzepatide, retatrutide or the others covered on this site) on California's schedules or in a California-specific ban as of September 2026. That is the position in most states.

Human growth hormone

Human growth hormone is not in § 11056. Human chorionic gonadotropin was Schedule III until AB 1152 removed it effective 1 January 2026; subsection (f) now reads anabolic steroids and chorionic gonadotropin except for human chorionic gonadotropin. (Health & Safety Code § 11056(f), as amended by AB 1152 (Stats. 2025, ch. 183), effective 1 January 2026) (leginfo.legislature.ca.gov)

Compounded semaglutide and tirzepatide

2025-10-01. The Board of Pharmacy adopted revised compounding regulations on 17 June 2025 (16 CCR §§ 1735.1, 1736.1, 1735.8 and 1736.8), effective 1 October 2025: a compound with the same active ingredient as a commercial product is essentially a copy unless the pharmacist verifies and documents a clinically significant, patient-specific difference, and certificates of analysis must name the actual manufacturer of the active ingredient. The rules are aimed at compounded semaglutide and tirzepatide. (frierlevitt.com)

This is about licensed pharmacies and prescriptions. It does not make a research vial legal or illegal; those sit under the federal unapproved-drug rules described above.

Clinics, medspas and prescribers

No California medical board guidance specific to peptide therapy was located. A California prescriber who administers BPC-157 or another unapproved peptide is exposed under the state's medical practice act and, since the FDA's 2026 letters, under federal law; the July 2026 advisory vote has not changed that yet.

Buying, possessing and using research peptides in California

Business and Professions Code § 4060 bars possession of controlled substances without a prescription; no equivalent California offence was found for possessing non-controlled, unscheduled peptides, so the federal rules, which fall on the seller, apply. (leginfo.legislature.ca.gov)

Ordering from a vendor in another state. Almost every research-peptide order into California is interstate commerce, which is exactly what the FDCA governs. The risk sits with the vendor: the FDA's letters name the seller, and Eli Lilly said in August 2026 it had referred more than 200 sellers to the FDA, the DOJ, state attorneys general and licensing boards. Connecticut's attorney general has already used state consumer-protection law against a "research grade" GLP-1 seller (2025), which is the template other states can copy. The Bureau's vendor scorecard notes which vendors publish batch testing; none of the scored vendors appears in the tracker as of September 2026.

GLP-1 drugs by prescription. Yes. Business and Professions Code § 2242 requires an appropriate prior examination before prescribing, which does not require a synchronous interaction and may be done by telehealth, including a questionnaire, if the standard of care is met. Out-of-state pharmacies shipping compounded products into California need a nonresident pharmacy permit. (leginfo.legislature.ca.gov) The branded pens are the only fully approved route; compounded versions are now on the wrong side of the FDA's shortage rules.

Sports and employment testing are not a California law question. Growth hormone secretagogues and GHRH analogues are on the WADA Prohibited List everywhere; a standard workplace panel does not screen for peptides. The national legal guide covers both.

Not sure which of these you actually need?

Answer five questions about your goal, experience and budget and the Stack Builder shows you a matched research protocol on screen, with the compounds, cycle shape and vendor picks from the vendors we score.

Build your stack, 2 minutes

Enforcement in California

2025-06-23. The Board of Pharmacy issued a cease-and-desist order against Boothwyn Pharmacy LLC, a Pennsylvania nonresident sterile compounder, for shipping compounded sterile products to California before endotoxin results were in and for labelling semaglutide and tirzepatide products store frozen; the order was lifted on 10 July 2025 after a hearing. (pharmacy.ca.gov)

A warning letter, lawsuit or board complaint is an allegation by the body that issued it, not a court finding, unless the entry says otherwise.

Editor's note. AB 1990 (2025 to 2026 session), which would add sourcing, certificate-of-analysis and advertising-disclosure rules for compounded weight-management drugs with penalties per dose, was still pending in the Senate as of June 2026. Older articles still call hCG Schedule III in California; that changed on 1 January 2026.

Frequently asked questions

Is BPC-157 legal in California?

California has not scheduled BPC-157, so possessing it is not a California offence. Federally it is an unapproved new drug: selling it for human use is a violation by the seller, and licensed pharmacies cannot compound it because it is not on the 503A bulks list, despite the advisory committee's July 2026 recommendation. Research vendors sell it under a research-use-only label, which the FDA's 2026 letters treat as no defence when the site shows human use.

Can I get semaglutide or tirzepatide by telehealth in California?

Yes. Business and Professions Code § 2242 requires an appropriate prior examination before prescribing, which does not require a synchronous interaction and may be done by telehealth, including a questionnaire, if the standard of care is met. Out-of-state pharmacies shipping compounded products into California need a nonresident pharmacy permit. The California Board of Pharmacy position on compounded versions: The Board of Pharmacy adopted revised compounding regulations on 17 June 2025 (16 CCR §§ 1735.1, 1736.1, 1735.8 and 1736.8), effective 1 October 2025: a compound with the same active ingredient as a commercial product is essentially a copy unless the pharmacist verifies and documents a clinically significant, patient-specific difference, and certificates of analysis must name the actual manufacturer of the active ingredient. The rules are aimed at compounded semaglutide and tirzepatide.

Is HGH legal in California?

Only with a valid prescription for an approved use. California does not schedule it separately, but federal law, 21 U.S.C. section 333(e), makes distribution or possession for any non-approved use a federal offence. Sermorelin, ipamorelin and CJC-1295 are not HGH and fall under the general unapproved-drug rules instead.

Sources

Every California fact above was checked against the linked source on 28 September 2026. If a statute or board position has changed, email [email protected] with the link and the page will be corrected and dated.